Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: Antibody targeting to the lung induces ACE antigenic modulation

Sergei Danilov, Elena Nikolaevna Atochina, Holger Hiemisch, Tatiana Churak-ova, Aygul Moldobayeva, Ivan Sakharov, Galina Deichman, Una Ryan, Viadimir R. Muzykantov

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We previously described that mAb to angiotensin-convertlng enzyme (ACE), mAb 9B9, accumulates in the rat lungs after systemic injection. In the present work we have documented that mAb 9B9 cross-reacts with human, monkey, rat, cat and hamster ACE, while other ACE antibodies did not cross-react with the rat, cat and hamster enzyme. Anti-ACE mAb 3A5 and I2H5 inhibit human ACE in vitro, while mAb 9B9 does not inhibit ACE activity. Radiolabeled mAb 9B9, but not other antibodies, accumulates selectively in rat, cat and hamster lungs after systemic administration. No accumulation of mAb 9B9 has been observed in hamster kidney, while hamster kidney ACE activity is higher than that in the lung. mAb 9B9 does not induce complement-mediated injury to cultured endothellal cells. No pathological changes were detected in organs of animals after mAb 9B9 injection (10-100 mg/kg). However, injection of these amounts of mAb 9B9 leads to a decrease in ACE activity in the lung homogenates and an increase in serum. In cultured human endothellal cells treatment with mAb 9B9 increases ACE activity in cell medium and decreases in cell lysates. Therefore, while mAb 9B9 does not kill endothellal cells, at high dose it may induce ACE shedding from the cell. The results obtained support the potential of anti-ACE mAb 9B9 for targeting to the lung and for investigations of the pulmonary endothelium.

Original languageEnglish
Pages (from-to)1153-1160
Number of pages8
JournalInternational Immunology
Volume6
Issue number8
DOIs
Publication statusPublished - Aug 1994
Externally publishedYes

Fingerprint

Antigenic Modulation
Angiotensin
Peptidyl-Dipeptidase A
Antigens
Lung
Antibody
Antibodies
Enzymes
Modulation
Enzyme activity
Interaction
Cricetinae
Rats
Cats
Cell
Injection
Injections
Kidney
Accumulate
In Vitro Techniques

Keywords

  • ACE
  • Antigenic modulation
  • Biodistribution
  • Drug targeting
  • Endothelium
  • Lung

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Transplantation
  • Immunology

Cite this

Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo : Antibody targeting to the lung induces ACE antigenic modulation. / Danilov, Sergei; Atochina, Elena Nikolaevna; Hiemisch, Holger; Churak-ova, Tatiana; Moldobayeva, Aygul; Sakharov, Ivan; Deichman, Galina; Ryan, Una; Muzykantov, Viadimir R.

In: International Immunology, Vol. 6, No. 8, 08.1994, p. 1153-1160.

Research output: Contribution to journalArticle

Danilov, Sergei ; Atochina, Elena Nikolaevna ; Hiemisch, Holger ; Churak-ova, Tatiana ; Moldobayeva, Aygul ; Sakharov, Ivan ; Deichman, Galina ; Ryan, Una ; Muzykantov, Viadimir R. / Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo : Antibody targeting to the lung induces ACE antigenic modulation. In: International Immunology. 1994 ; Vol. 6, No. 8. pp. 1153-1160.
@article{dd20a23a7b92471d986e503d12d89120,
title = "Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: Antibody targeting to the lung induces ACE antigenic modulation",
abstract = "We previously described that mAb to angiotensin-convertlng enzyme (ACE), mAb 9B9, accumulates in the rat lungs after systemic injection. In the present work we have documented that mAb 9B9 cross-reacts with human, monkey, rat, cat and hamster ACE, while other ACE antibodies did not cross-react with the rat, cat and hamster enzyme. Anti-ACE mAb 3A5 and I2H5 inhibit human ACE in vitro, while mAb 9B9 does not inhibit ACE activity. Radiolabeled mAb 9B9, but not other antibodies, accumulates selectively in rat, cat and hamster lungs after systemic administration. No accumulation of mAb 9B9 has been observed in hamster kidney, while hamster kidney ACE activity is higher than that in the lung. mAb 9B9 does not induce complement-mediated injury to cultured endothellal cells. No pathological changes were detected in organs of animals after mAb 9B9 injection (10-100 mg/kg). However, injection of these amounts of mAb 9B9 leads to a decrease in ACE activity in the lung homogenates and an increase in serum. In cultured human endothellal cells treatment with mAb 9B9 increases ACE activity in cell medium and decreases in cell lysates. Therefore, while mAb 9B9 does not kill endothellal cells, at high dose it may induce ACE shedding from the cell. The results obtained support the potential of anti-ACE mAb 9B9 for targeting to the lung and for investigations of the pulmonary endothelium.",
keywords = "ACE, Antigenic modulation, Biodistribution, Drug targeting, Endothelium, Lung",
author = "Sergei Danilov and Atochina, {Elena Nikolaevna} and Holger Hiemisch and Tatiana Churak-ova and Aygul Moldobayeva and Ivan Sakharov and Galina Deichman and Una Ryan and Muzykantov, {Viadimir R.}",
year = "1994",
month = "8",
doi = "10.1093/intimm/6.8.1153",
language = "English",
volume = "6",
pages = "1153--1160",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo

T2 - Antibody targeting to the lung induces ACE antigenic modulation

AU - Danilov, Sergei

AU - Atochina, Elena Nikolaevna

AU - Hiemisch, Holger

AU - Churak-ova, Tatiana

AU - Moldobayeva, Aygul

AU - Sakharov, Ivan

AU - Deichman, Galina

AU - Ryan, Una

AU - Muzykantov, Viadimir R.

PY - 1994/8

Y1 - 1994/8

N2 - We previously described that mAb to angiotensin-convertlng enzyme (ACE), mAb 9B9, accumulates in the rat lungs after systemic injection. In the present work we have documented that mAb 9B9 cross-reacts with human, monkey, rat, cat and hamster ACE, while other ACE antibodies did not cross-react with the rat, cat and hamster enzyme. Anti-ACE mAb 3A5 and I2H5 inhibit human ACE in vitro, while mAb 9B9 does not inhibit ACE activity. Radiolabeled mAb 9B9, but not other antibodies, accumulates selectively in rat, cat and hamster lungs after systemic administration. No accumulation of mAb 9B9 has been observed in hamster kidney, while hamster kidney ACE activity is higher than that in the lung. mAb 9B9 does not induce complement-mediated injury to cultured endothellal cells. No pathological changes were detected in organs of animals after mAb 9B9 injection (10-100 mg/kg). However, injection of these amounts of mAb 9B9 leads to a decrease in ACE activity in the lung homogenates and an increase in serum. In cultured human endothellal cells treatment with mAb 9B9 increases ACE activity in cell medium and decreases in cell lysates. Therefore, while mAb 9B9 does not kill endothellal cells, at high dose it may induce ACE shedding from the cell. The results obtained support the potential of anti-ACE mAb 9B9 for targeting to the lung and for investigations of the pulmonary endothelium.

AB - We previously described that mAb to angiotensin-convertlng enzyme (ACE), mAb 9B9, accumulates in the rat lungs after systemic injection. In the present work we have documented that mAb 9B9 cross-reacts with human, monkey, rat, cat and hamster ACE, while other ACE antibodies did not cross-react with the rat, cat and hamster enzyme. Anti-ACE mAb 3A5 and I2H5 inhibit human ACE in vitro, while mAb 9B9 does not inhibit ACE activity. Radiolabeled mAb 9B9, but not other antibodies, accumulates selectively in rat, cat and hamster lungs after systemic administration. No accumulation of mAb 9B9 has been observed in hamster kidney, while hamster kidney ACE activity is higher than that in the lung. mAb 9B9 does not induce complement-mediated injury to cultured endothellal cells. No pathological changes were detected in organs of animals after mAb 9B9 injection (10-100 mg/kg). However, injection of these amounts of mAb 9B9 leads to a decrease in ACE activity in the lung homogenates and an increase in serum. In cultured human endothellal cells treatment with mAb 9B9 increases ACE activity in cell medium and decreases in cell lysates. Therefore, while mAb 9B9 does not kill endothellal cells, at high dose it may induce ACE shedding from the cell. The results obtained support the potential of anti-ACE mAb 9B9 for targeting to the lung and for investigations of the pulmonary endothelium.

KW - ACE

KW - Antigenic modulation

KW - Biodistribution

KW - Drug targeting

KW - Endothelium

KW - Lung

UR - http://www.scopus.com/inward/record.url?scp=0027933741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027933741&partnerID=8YFLogxK

U2 - 10.1093/intimm/6.8.1153

DO - 10.1093/intimm/6.8.1153

M3 - Article

C2 - 7981144

AN - SCOPUS:0027933741

VL - 6

SP - 1153

EP - 1160

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 8

ER -